

Advancing critical care worldwide through partnership, innovation, and purpose.
At Piramal Critical Care, saving and improving patients’ lives is more than a mission it is the foundation of everything we do. We collaborate with pharmaceutical and biotech partners to expand global access to differentiated critical care therapies.
Over the years, we have built a strong platform through strategic partnerships, acquisitions, and licensing initiatives that complement our capabilities in complex hospital generics and critical care. Our Business Development team actively engages with partners who share our commitment to quality, reliability, and meaningful patient impact.

Piramal Critical Care is a global leader in inhaled anesthetics and a key player in hospital based critical care therapies, with a presence across the United States, Europe, and key emerging markets. Our portfolio spans anesthesia, pain management, intrathecal therapies, anti-infectives, neuromuscular blockers, and supportive care products.
We combine deep therapeutic expertise with a robust commercial infrastructure, regulatory excellence, and vertically integrated manufacturing to reliably bring complex products to market worldwide.

Our objective is to build sustainable, value creating partnerships that address unmet needs in acute and critical care settings. We actively evaluate opportunities aligned with our focus on critical care and hospital-based therapies, including

Each opportunity is assessed based on strategic alignment, long-term value creation, and global scalability. We remain open to a range of flexible collaboration models, including
Partners choose Piramal Critical Care for our ability to execute:

We bring more than capital we bring operational depth, market access, and a commitment to shared success.
Our Business Development team works closely with internal technical, regulatory, commercial, and legal teams to evaluate opportunities efficiently and transparently. We focus on building partnerships that are scientifically sound, commercially viable, and aligned with our mission to improve patient outcomes.


We welcome collaboration opportunities in critical care.